Penumbra Inc(PEN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 79.87 | EPS (ttm) | 4.07 | Insider Own | 2.87% | Shs Outstand | 39.4M | Perf Week | 0.87% |
| Market Cap | 12.81B | Forward P/E | 54.29 | EPS next Y | 26.06% | Insider Trans | - | Shs Float | 38.3M | Perf Month | 1.99% |
| Enterprise Value | 12.36B | PEG | 2.46 | EPS next Q | 1.2 | Inst Own | 87.22% | Short Float | 5.87% | Perf Quarter | 1.63% |
| Income | 0.16B | P/S | 8.51 | EPS this Y | 23.75% | Inst Trans | 1.81% | Short Ratio | 6.8 | Perf Half Y | -0.84% |
| Sales | 1.50B | P/B | 8.37 | EPS next 5Y | 22.07% | ROA | 8.8% | Short Interest | 2.25M | Perf YTD | 4.6% |
| Book/sh | 38.86 | P/C | 19.45 | EPS past 3/5Y | - | ROE | 11.37% | 52W High | -10.26% ($362.41) | Perf Year | 28.55% |
| Cash/sh | 16.72 | P/FCF | 59.33 | Sales past 3/5Y | 18.33% 20.16% | ROIC | 9.3% | 52W Low | 46.99% ($221.26) | Perf 3Y | 68.44% |
| Dividend Est. | - | EV/EBITDA | 60.47 | EPS Y/Y TTM | 7.09% | Gross Margin | 66.72% | Volatility(W/M) | 0.61% 0.54% | Perf 5Y | 18.03% |
| Dividend TTM | - | EV/Sales | 8.22 | Sales Y/Y TTM | 17.55% | Oper. Margin | 12.45% | ATR (14) | 1.89 | Perf 10Y | 386.49% |
| Dividend Ex-Date | - | Quick Ratio | 3.86 | EPS Q/Q | -23.74% | Profit Margin | 10.67% | RSI (14) | 66.72 | Recom | 2.8 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.75 | Sales Q/Q | 14.9% | SMA20 | 1.5% ($320.41) | Beta | 0.7 | Target Price | $364.25 |
| Payout | - | Debt/Eq | 0.14 | Earnings | 2026/7/30 | SMA50 | 1.35% ($320.89) | Rel Volume | 1.31 | Prev Close | $324.39 |
| Employees | 4700 | LT Debt/Eq | 0.13 | EPS/Sales Surpr. | -24.3% 0.1% | SMA200 | -0.65% ($327.35) | Avg Volume(3M) | 0.33M | Price | $325.22 |
| IPO | 2015/9/18 | Option/Short | Yes/Yes | Trades | 9348 | Volume | 434,251 | Change | 0.26% |
A U.S. medical device company specializing in vascular interventional devices, focused on developing and supplying treatments for stroke and peripheral vascular disease, with thrombectomy devices that suction and remove blood clots from inside vessels as its core product.
Over the past 1 year, roughly in the middle
10% below its 1-year high.
Traded more than usual. That is 131% of its average volume.
PEN makes money exceptionally well
Of every $100 in sales, $12.45 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +23.8% this year.
Tap to view numbers
However, it looks expensive
For a company earning $100 a year, you would pay $7,987. Peers typically go for $2,813. Compared with its own 4-year average, it is 63% cheaper now.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +18.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 87.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
RSBA Return Stacked Bonds & Merger Arbitrage ETF 0.05% 
TMFS Motley Fool Small-Cap Growth ETF 0.03% 
NEWZ StockSnips AI-Powered Sentiment US All Cap ETF 0.03% 
CSMD Congress SMid Growth ETF 0.03% 
ARB AltShares Merger Arbitrage ETF 0.03% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
OPEX Tradr 2X Long OPEN Daily ETF 3M 
PENU T-REX 2X Long PENG Daily Target ETF 2M 
OPEG Leverage Shares 2X Long OPEN Daily ETF 1M It ranks #11 of 141 in the industry
Based on market cap of $13B.
PEN#11 Penumbra Inc $13B PER 79.9 
SNN#12 Smith & Nephew plc ADR $13B PER 20.8 
GMED#13 Globus Medical Inc $11B PER 20.9 
GKOS#14 Glaukos Corp $11B PER - 
PODD#15 Insulet Corp $10B PER 29.6 
FAQ
What kind of company is PEN?
PEN belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of PEN?
The market cap of PEN is approximately $12.8B, ranking 772 within its sector.
What is the P/E ratio of PEN?
PEN has a P/E ratio of approximately 79.9x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for PEN?
PEN has recorded a 52-week high of $362.41 and a low of $221.26.
